CL2019003264A1 - Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151) - Google Patents

Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)

Info

Publication number
CL2019003264A1
CL2019003264A1 CL2019003264A CL2019003264A CL2019003264A1 CL 2019003264 A1 CL2019003264 A1 CL 2019003264A1 CL 2019003264 A CL2019003264 A CL 2019003264A CL 2019003264 A CL2019003264 A CL 2019003264A CL 2019003264 A1 CL2019003264 A1 CL 2019003264A1
Authority
CL
Chile
Prior art keywords
preparing
methods
same
formulations
vaccines against
Prior art date
Application number
CL2019003264A
Other languages
English (en)
Inventor
Edward F Fritsch
Original Assignee
Broad Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broad Inst Inc filed Critical Broad Inst Inc
Publication of CL2019003264A1 publication Critical patent/CL2019003264A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA FORMULACIÓN PARA COMPOSICIÓN DE VACUNA O COMPOSICIÓN INMUNÓGENA CONTRA LA NEOPLASIA PARA EL TRATAMIENTO O PREVENCIÓN DE LA NEOPLASIA EN UN SUJETO Y A MÉTODOS PARA PREPARAR LA MISMA.
CL2019003264A 2015-06-09 2019-11-14 Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151) CL2019003264A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562172890P 2015-06-09 2015-06-09
CL2017003151A CL2017003151A1 (es) 2015-06-09 2017-12-07 Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas

Publications (1)

Publication Number Publication Date
CL2019003264A1 true CL2019003264A1 (es) 2020-02-14

Family

ID=56236097

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017003151A CL2017003151A1 (es) 2015-06-09 2017-12-07 Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
CL2019003264A CL2019003264A1 (es) 2015-06-09 2019-11-14 Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2017003151A CL2017003151A1 (es) 2015-06-09 2017-12-07 Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas

Country Status (19)

Country Link
US (1) US20190060428A1 (es)
EP (1) EP3307303A2 (es)
JP (2) JP2018521028A (es)
KR (1) KR20180016531A (es)
CN (1) CN107921107A (es)
AU (1) AU2016276704A1 (es)
CA (1) CA2988135A1 (es)
CL (2) CL2017003151A1 (es)
CO (1) CO2017012893A2 (es)
CR (1) CR20180015A (es)
EC (1) ECSP18001613A (es)
HK (2) HK1252325A1 (es)
IL (1) IL256173A (es)
MX (1) MX2017015881A (es)
PE (1) PE20180601A1 (es)
PH (1) PH12017502233A1 (es)
RU (2) RU2753246C2 (es)
TW (2) TW202241500A (es)
WO (1) WO2016201049A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2564841T3 (es) 2010-05-14 2016-03-29 The General Hospital Corporation Composiciones y métodos para identificar neoantígenos específicos de un tumor
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
WO2015095811A2 (en) 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
MX2017014700A (es) 2015-05-20 2018-08-15 Broad Inst Inc Neoantigenos compartidos.
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US11861491B2 (en) 2017-10-16 2024-01-02 Illumina, Inc. Deep learning-based pathogenicity classifier for promoter single nucleotide variants (pSNVs)
CN113627458A (zh) 2017-10-16 2021-11-09 因美纳有限公司 基于循环神经网络的变体致病性分类器
WO2019204663A1 (en) * 2018-04-19 2019-10-24 Neon Therapeutics, Inc. Peptide formulations and uses thereof
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
CN110514845B (zh) * 2019-08-22 2022-09-27 深圳新合睿恩生物医疗科技有限公司 一种肿瘤新生抗原免疫原性检测方法及检测平台
GB202104715D0 (en) 2021-04-01 2021-05-19 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
CN113461805B (zh) * 2021-09-02 2021-12-10 广州吉妮欧生物科技有限公司 一种嵌入抗原表位肽的荧光素酶及其构建方法和应用
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US7767449B1 (en) 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
CA2005291C (en) 1988-12-30 1999-01-26 Beverly Dale Feline infectious peritonitis virus diagnostic tools
US6780407B1 (en) 1989-03-08 2004-08-24 Aventis Pasteur Pox virus comprising DNA sequences encoding CEA and B7 antigen
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0452457T3 (da) 1989-11-03 1998-03-02 Univ Vanderbilt Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US6309647B1 (en) 1999-07-15 2001-10-30 Aventis Pasteur Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
US6277558B1 (en) 1990-11-30 2001-08-21 Kansas University Medical Center α-3 chain type IV collagen polynucleotides
AU1588092A (en) 1991-02-22 1992-09-15 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Transmission blocking vaccine against malaria
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US5756101A (en) 1991-07-01 1998-05-26 Pasteur Merieux Serums Et Vaccins Malaria recombinant poxvirus
US5766597A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Malaria recombinant poxviruses
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
WO1995030018A2 (en) 1994-04-29 1995-11-09 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US6924128B2 (en) 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5820869A (en) 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
US5849303A (en) 1995-06-07 1998-12-15 American Home Products Corporation Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
FR2750865B1 (fr) 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
WO1998017815A1 (en) 1996-10-17 1998-04-30 Oxford Biomedica (Uk) Limited Retroviral vectors
US7198784B2 (en) 1996-10-17 2007-04-03 Oxford Biomedica (Uk) Limited Retroviral vectors
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6004777A (en) 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
CA2304168A1 (en) 1997-09-19 1999-04-01 The Trustees Of The University Of Pennsylvania Methods and cell line useful for production of recombinant adeno-associated viruses
US6346415B1 (en) 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6893865B1 (en) 1999-04-28 2005-05-17 Targeted Genetics Corporation Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6793926B1 (en) 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
DK1180159T3 (da) 1999-05-28 2008-11-17 Targeted Genetics Corp Fremgangsmåder og sammensætninger til at sænke niveauet af Tumor-Nekrose-Faktor (TNF) i TNF-associerede lidelser
US7115391B1 (en) 1999-10-01 2006-10-03 Genovo, Inc. Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
PL205922B1 (pl) 2000-03-14 2010-06-30 Bavarian Nordic As Zmodyfikowany wirus Ankara (MVA), zakażona nim komórka gospodarza, jego zastosowania, kompozycja farmaceutyczna i sposoby otrzymywania wirusa oraz sekwencji kwasu nukleinowego, peptydu i/lub polipeptydu
IL154712A0 (en) 2000-11-23 2003-10-31 Bavarian Nordic As Modified vaccinia ankara virus variant
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7097842B2 (en) 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US20030104008A1 (en) 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
EP1420822B2 (en) 2002-04-19 2017-07-05 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
EP1651265B1 (en) 2003-07-24 2008-04-23 Merial Limited Vaccine formulations comprising an oil-in-water emulsion
RU2285548C2 (ru) * 2004-10-25 2006-10-20 Георгий Цыренович Дамбаев Способ лечения онкозаболеваний
ES2937245T3 (es) 2005-08-23 2023-03-27 Univ Pennsylvania ARN que contiene nucleósidos modificados y métodos de uso del mismo
EP2131857B1 (en) * 2007-03-22 2015-07-29 The Regents of the University of Colorado, a body corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
AU2008346801A1 (en) 2007-12-31 2009-07-16 Nanocor Therapeutics, Inc. RNA interference for the treatment of heart failure
ES2564841T3 (es) * 2010-05-14 2016-03-29 The General Hospital Corporation Composiciones y métodos para identificar neoantígenos específicos de un tumor
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
GB201022147D0 (en) * 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
HRP20211595T1 (hr) * 2011-05-24 2022-01-21 BioNTech SE Individualizirana cjepiva protiv raka
KR20230145545A (ko) * 2013-04-07 2023-10-17 더 브로드 인스티튜트, 인코퍼레이티드 개인맞춤화 신생물 백신을 위한 조성물 및 방법
ES2921531T3 (es) * 2013-12-06 2022-08-29 Broad Inst Inc Formulaciones para vacunas contra la neoplasia

Also Published As

Publication number Publication date
RU2021122284A (ru) 2021-10-21
CN107921107A (zh) 2018-04-17
RU2753246C2 (ru) 2021-08-12
JP2021152053A (ja) 2021-09-30
RU2017145963A3 (es) 2019-07-17
PH12017502233A1 (en) 2018-06-25
TW201718000A (zh) 2017-06-01
AU2016276704A1 (en) 2017-12-14
HK1252325A1 (zh) 2019-05-24
MX2017015881A (es) 2018-04-18
WO2016201049A3 (en) 2017-02-09
CL2017003151A1 (es) 2018-04-06
HK1253271A1 (zh) 2019-06-14
WO2016201049A2 (en) 2016-12-15
EP3307303A2 (en) 2018-04-18
RU2017145963A (ru) 2019-07-16
JP2018521028A (ja) 2018-08-02
PE20180601A1 (es) 2018-04-09
KR20180016531A (ko) 2018-02-14
CR20180015A (es) 2018-03-20
US20190060428A1 (en) 2019-02-28
TW202241500A (zh) 2022-11-01
CO2017012893A2 (es) 2018-05-21
CA2988135A1 (en) 2016-12-15
TWI750122B (zh) 2021-12-21
ECSP18001613A (es) 2018-05-31
IL256173A (en) 2018-02-28

Similar Documents

Publication Publication Date Title
CL2019003264A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)
CL2018000320A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
EP4233898A3 (en) Influenza mrna vaccines
MX2017009308A (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
BR112016012862A2 (pt) formulações para vacinas para neoplasia
BR112017023161A2 (pt) composições de ácido obeticólico e métodos de uso
EP3916091A3 (en) Dry powder composition comprising long-chain rna
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
PE20151867A1 (es) Polipeptidos f de prefusion del virus sincicial respiratorio (rsv )solubles y estabilizados
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
PE20151588A1 (es) Vacuna contra el virus del dengue
GT201700179A (es) Formulaciones en polvo nasal para el tratamiento de hipoglicemia
MX2022009155A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
AR102547A1 (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
CL2018002692A1 (es) Vacuna bivalente contra el virus de gripe porcina.(divisional solicitud 201701961)
CL2015001562A1 (es) Método para obtener una vacuna de mycoplasma.
GB2539148A (en) Vaccine compositions
CU20180025A7 (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
BR112017009510A2 (pt) composições compreendendo ciclosporina
AU2016248452A8 (en) Bordetella pertussis immunogenic vaccine compositions
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CO2017003840A2 (es) Formulación esterilizada por calor que comprende quitosán y proceso para preparación de la misma
CR20160495A (es) Composiciones libres de células para la restauración de células y métodos para la preparación y utilización de las mismas
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação